DE60139959D1 - Nukleinsäureadjuvantien - Google Patents

Nukleinsäureadjuvantien

Info

Publication number
DE60139959D1
DE60139959D1 DE60139959T DE60139959T DE60139959D1 DE 60139959 D1 DE60139959 D1 DE 60139959D1 DE 60139959 T DE60139959 T DE 60139959T DE 60139959 T DE60139959 T DE 60139959T DE 60139959 D1 DE60139959 D1 DE 60139959D1
Authority
DE
Germany
Prior art keywords
nucleic acid
molecules
truncated
coding region
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60139959T
Other languages
English (en)
Inventor
Joel R Haynes
Joshua E Arrington
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Powderject Vaccines Inc
Original Assignee
Powderject Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Powderject Vaccines Inc filed Critical Powderject Vaccines Inc
Application granted granted Critical
Publication of DE60139959D1 publication Critical patent/DE60139959D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60139959T 2000-11-27 2001-11-26 Nukleinsäureadjuvantien Expired - Lifetime DE60139959D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72431500A 2000-11-27 2000-11-27
PCT/US2001/043151 WO2003004055A2 (en) 2000-11-27 2001-11-26 Nucleic acid adjuvants

Publications (1)

Publication Number Publication Date
DE60139959D1 true DE60139959D1 (de) 2009-10-29

Family

ID=24909936

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60139959T Expired - Lifetime DE60139959D1 (de) 2000-11-27 2001-11-26 Nukleinsäureadjuvantien

Country Status (16)

Country Link
EP (1) EP1379273B1 (de)
JP (1) JP4221289B2 (de)
KR (1) KR20040045391A (de)
CN (1) CN1317034C (de)
AT (1) ATE442858T1 (de)
AU (1) AU2001297988B2 (de)
BR (1) BR0115646A (de)
CA (1) CA2429708A1 (de)
DE (1) DE60139959D1 (de)
DK (1) DK1379273T3 (de)
ES (1) ES2332261T3 (de)
IL (2) IL156041A0 (de)
MX (1) MXPA03004638A (de)
NZ (1) NZ526175A (de)
PT (1) PT1379273E (de)
WO (1) WO2003004055A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA010056B1 (ru) 2003-10-10 2008-06-30 Паудерджект Вэксинс, Инк. Конструкции нуклеиновых кислот
RU2380375C2 (ru) 2004-02-11 2010-01-27 Иституто Ди Ричерке Ди Биолоджиа Молеколаре П Анджелетти Спа Слитые белки карциноэмбрионального антигена
GB0507997D0 (en) * 2005-02-01 2005-05-25 Powderject Vaccines Inc Nucleic acid constructs
US8389686B2 (en) 2008-05-07 2013-03-05 Osaka University Noncovalent collagen crosslinking agent
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
US9090691B2 (en) 2010-09-15 2015-07-28 Applied Molecular Transport Llc Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences
CN103060253A (zh) * 2013-01-24 2013-04-24 麻丽丹 霍乱弧菌ctxAB基因的质粒克隆菌株以及制备方法和应用
BR112016025866A2 (pt) 2014-05-07 2017-12-12 Applied Molecular Transp Llc composição farmacêutica, método para tratar uma doença anti-inflamatória em um indivíduo, método para tratar uma doença autoimune em um indivíduo, método para tratar um câncer em um indivíduo, uso de uma molécula de fusão que não ocorre naturalmente, método para tratar um distúrbio metabólico em um indivíduo, método para tratar uma doença hepática gordurosa em um indivíduo, método para tratar um distúrbio de deficiência de hormônio de crescimentoem um indivíduo, e, polinucleotídeo que codifica uma molécula de fusão
CN112105376A (zh) 2018-03-08 2020-12-18 应用分子运输公司 用于经口递送的毒素衍生的递送构建体
WO2020097394A1 (en) 2018-11-07 2020-05-14 Applied Molecular Transport Inc. Delivery constructs for transcytosis and related methods
TW202120521A (zh) 2019-08-16 2021-06-01 美商應用分子運輸公司 組合物、配方及介白素生產及純化

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
TW404844B (en) 1993-04-08 2000-09-11 Oxford Biosciences Ltd Needleless syringe
GB9416663D0 (en) 1994-08-17 1994-10-12 Oxford Bioscience Limited Particle delivery
DE69507321T2 (de) 1994-10-24 1999-07-15 Powderject Res Ltd Nadellose spritze
GB9426379D0 (en) 1994-12-23 1995-03-01 Oxford Biosciences Ltd Particle delivery
US6056960A (en) * 1995-06-07 2000-05-02 Kaslow; Harvey R. Compositions exhibiting ADP-ribosyltransferase activity and methods for the preparation and use thereof
GB9612629D0 (en) 1996-06-17 1996-08-21 Oxford Biosciences Ltd Method for providing dense particle compositions for use in transdermal particle delivery
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization

Also Published As

Publication number Publication date
CN1317034C (zh) 2007-05-23
KR20040045391A (ko) 2004-06-01
CN1537013A (zh) 2004-10-13
CA2429708A1 (en) 2003-01-16
PT1379273E (pt) 2009-11-27
IL156041A (en) 2010-05-17
JP4221289B2 (ja) 2009-02-12
NZ526175A (en) 2006-01-27
EP1379273A2 (de) 2004-01-14
MXPA03004638A (es) 2004-04-20
ATE442858T1 (de) 2009-10-15
EP1379273B1 (de) 2009-09-16
ES2332261T3 (es) 2010-02-01
WO2003004055A3 (en) 2003-11-20
BR0115646A (pt) 2005-12-13
AU2001297988B2 (en) 2006-10-26
DK1379273T3 (da) 2009-11-09
JP2004536107A (ja) 2004-12-02
IL156041A0 (en) 2003-12-23
WO2003004055A2 (en) 2003-01-16

Similar Documents

Publication Publication Date Title
CY1110982T1 (el) Συνθεσεις και μεθοδοι για την αυξηση της ασβεστοποιησεως των οστων
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
BR9906927A (pt) Proteìnas de neisseria meningitidis
ATE357511T1 (de) Dipeptidylpeptidasen
DK1187591T3 (da) IBD-associerede mikrobielle antigener og fremgangsmåder til at anvende samme
ATE491471T1 (de) Adjuvantien für dns impstoffe basierend auf imidazochinoline
NZ335485A (en) Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
NZ540544A (en) Nucleic acids and proteins from streptococcus groups A & B
DE60139959D1 (de) Nukleinsäureadjuvantien
DK0726955T3 (da) Kimære proteiner, som omfatter Borreliapolypeptider, og anvendelser heraf
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
DK1379550T3 (da) Et kimært protein omfattende non-toxisk pseudomonas exotoxin A og en type IV pilin sekvenser
ES2152251T3 (es) Variantes del dominio lectina de la selectina.
NZ500540A (en) Purified proteins, fusion proteins, recombinant vector, vaccine, kit, comprising proteins from Actinobacillus pleuropneumoniae
DK1119630T3 (da) Nukleinsyrekonstruktioner til genetisk immunisering
MXPA01008605A (es) Proteina de enlace del antigeno goodpasture.
FR2710074B1 (fr) Gène GRB3-3, ses variants et leurs utilisations.
DK0811071T3 (da) Amplifikeringssekvenser hidrørende fra desmin-genet, vektorer indeholdende disse sekvenser og anvendelse heraf til fremstilling af proteiner
DE69840326D1 (de) Steigerung der immunantwort unter verwendung von zielgerichteten molekülen
WO2000063385A3 (en) Nucleic acid immunization
DK1279677T3 (da) GD3-mimetiske peptider
DE69836485D1 (de) Hepatitis e-virus aus dem schwein und dessen verwendungen
WO2000047227A3 (en) Mycobacterium tuberculosis, immunization
ATE414905T1 (de) Diabetesmodell
WO2002046378A3 (en) Alternative pol k nucleotide and amino acid sequence and methods for using

Legal Events

Date Code Title Description
8364 No opposition during term of opposition